Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1705 in Participants With Dyslipidemia
NCT06238466Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD-1705 in dyslipidemia (12 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events and serious adverse events at Day 141. Started Jan 2024; status: active, not recruiting.
02
Drugs
AZD-1705
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06238466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238466.